Sun Pharma Advanced Research shares tank 20% after psoriasis drug fails Phase 2 trials
Shares of
Sun Pharma Advanced Research
Company (SPARC), a unit of India's largest drug maker
Sun Pharmaceutical Industries
, tumbled as much as 20% on Wednesday to Rs 156.50 on the BSE after the company disclosed that its investigational drug SCD-044 failed to meet the main goals in late-stage clinical trials for psoriasis and atopic dermatitis.
In a filing released post-market hours on Tuesday, SPARC said, 'SPARC informs that its partner Sun Pharmaceutical Industries Limited (SPIL) announced the top-line results from the Phase 2 clinical trials evaluating Vibozilimod (SCD-044) for the treatment of moderate-to-severe Psoriasis (SOLARES PsO) and Atopic Dermatitis (SOLARES AD)."
"SPIL informed that both SOLARES PsO and SOLARES AD studies did not meet the primary endpoint of 75 per cent improvement in PASI (Psoriasis Area and Severity Index) score (> PASI75) at Week 16 and 75 per cent improvement in EASI (Eczema Area and Severity Index) score (>EASI75) at Week 16, respectively,' the company said.
The company further added, 'SPARC and SPIL will evaluate the appropriate next steps for SCD-044.'
SPARC confirmed that, given the failure to meet primary endpoints, the development of the drug, also known as Vibozilimod, is being discontinued, and no further clinical trials are planned. The setback is significant as the drug was seen as a key asset in the company's speciality pipeline.
Also read:
Flipkart exits Aditya Birla Fashion and Retail in Rs 582 crore bulk deal; ABFRL stock tumbles 11%
Over the past year,
SPARC shares
have declined about 3%, underperforming the benchmark Sensex, which has risen roughly 12% during the same period.
Surprise FDA inspection at Halol unit
Separately, CNBC-TV18 reported on Wednesday that a surprise inspection was underway at Sun Pharma's Halol facility, one of its largest manufacturing units, by three inspectors from the U.S. Food and Drug Administration.
The Halol unit was last inspected in May 2022 and is currently under an import alert following a warning letter from the regulator.
Also read |
Sensex will hit 1.5 lakh by 2030 & 3 lakh by 2035! Raamdeo Agrawal makes big prediction
About the drug and its target conditions
Vibozilimod was being developed as a treatment for psoriasis and atopic dermatitis, two chronic inflammatory skin conditions. Psoriasis is marked by raised, scaly plaques on the skin due to accelerated skin cell growth, often affecting the elbows, knees, scalp, and trunk. Atopic dermatitis, or eczema, typically involves dry, itchy, and inflamed skin, often beginning in childhood but potentially affecting people at any age.
The failure of the Phase 2 studies now casts uncertainty over SPARC's speciality drug pipeline, with investors and analysts awaiting further clarity on the company's next steps.
(
Disclaimer
: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Standard
14 minutes ago
- Business Standard
HDFC Bank Ltd soars 1.44%, rises for third straight session
HDFC Bank Ltd is quoting at Rs 1977.6, up 1.44% on the day as on 12:49 IST on the NSE. The stock is up 25.69% in last one year as compared to a 7.26% gain in NIFTY and a 13.62% gain in the Nifty Bank index. HDFC Bank Ltd rose for a third straight session today. The stock is quoting at Rs 1977.6, up 1.44% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.93% on the day, quoting at 24981.3. The Sensex is at 82143.11, up 0.86%. HDFC Bank Ltd has added around 1.64% in last one month. Meanwhile, Nifty Bank index of which HDFC Bank Ltd is a constituent, has added around 3.62% in last one month and is currently quoting at 55760.85, up 1.48% on the day. The volume in the stock stood at 92.87 lakh shares today, compared to the daily average of 101.58 lakh shares in last one month. The benchmark June futures contract for the stock is quoting at Rs 1981.4, up 1.17% on the day. HDFC Bank Ltd is up 25.69% in last one year as compared to a 7.26% gain in NIFTY and a 13.62% gain in the Nifty Bank index. The PE of the stock is 22.19 based on TTM earnings ending March 25.
Time of India
20 minutes ago
- Time of India
RBI repo rate cut is like BrahMos and Akash activated together: CIO says Rs 2.5 lakh crore liquidity push feels like a missile strike
In a major policy move aimed at boosting liquidity and credit growth, the Reserve Bank of India (RBI) on Friday reduced the Cash Reserve Ratio (CRR) by 100 basis points to 3 per cent and cut the repo rate by 50 basis points to 5.5 per cent. Together, these measures are expected to release over Rs 2.5 lakh crore into the banking system. RBI Governor Sanjay Malhotra said the CRR cut will be implemented in four phases and will help reduce funding costs for banks. RBI just activated BrahMos, Pinaka, and Akash together: CIO The market responded to the scale and coordination of the RBI's announcement. 'The RBI just activated BrahMos, Pinaka, and Akash together,' wrote the CIO of Complete Circle Consultants on X, comparing the liquidity move and rate cut to a multi-pronged strike. — PuneetSingh84 (@PuneetSingh84) Analysts believe the CRR cut alone could ease funding conditions by releasing ₹2.5 lakh crore into the system. This is likely to lower banks' cost of funds, improve net interest margins, and support their profitability. The banking sector is expected to channel the additional liquidity into sectors such as housing, automobiles, and small business loans. RBI announces staggered CRR cut to enhance liquidity The RBI's CRR reduction, from 4% to 3%, allows banks to retain more of their deposits instead of maintaining them with the central bank. With this change, banks are required to hold ₹3 for every ₹100 in deposits, down from ₹4. This frees up ₹1 that can be used for lending or investment. 'The combined measures aim to boost lending and ease monetary conditions,' Malhotra said at the Monetary Policy Committee (MPC) briefing in Mumbai. Live Events You Might Also Like: RBI's bazooka sends Sensex, Nifty soaring. What does it mean for stock market investors Unlike a repo rate cut , which influences lending rates indirectly, the CRR reduction provides immediate liquidity support. The central bank plans to implement the CRR cut in four stages to ensure stability while increasing the money available to banks. Repo rate cut to reduce borrowing costs The 50 basis point repo rate cut directly lowers the cost of borrowing. This is expected to benefit home loan borrowers with lower EMIs or shorter loan terms. Personal and auto loans may also become cheaper, increasing consumer demand and pushing credit growth further. By reducing the repo rate along with the CRR, the RBI has reinforced its support for economic expansion and recovery. Policy transmission to get a boost The CRR cut also improves monetary policy transmission. With additional liquidity, banks are more likely to pass on the benefits of the repo rate cut to borrowers. This is expected to make loans more affordable and stimulate economic activity. You Might Also Like: RBI MPC opts for a 'jumbo' rate cut to bring repo rate down to 5.5%, switches to neutral gear The RBI's dual move—cutting both the CRR and the repo rate—is viewed as a strong signal to the market that it remains focused on improving liquidity, encouraging credit offtake, and supporting broader growth.
Mint
21 minutes ago
- Mint
IndusInd Bank share price jumps over 5% after RBI Governor says lender's issue should ‘settle down soon'
IndusInd Bank share price jumped over 5% after the Reserve Bank of India's (RBI) officials, including Governor Sanjay Malhotra, commented on the private lender's recent crisis. IndusInd Bank shares rallied as much as 5.32% to ₹ 845.85 apiece on the BSE. In its post-monetary policy press conference, RBI Governor Sanjay Malhotra said that the issue at the IndusInd Bank should settle down very soon. 'IndusInd Bank has taken enough steps to improve accounting practices. The issue in the bank should settle down very soon. The bank is doing well on the whole,' Malhotra said. IndusInd Bank MD & CEO has resigned, which was good enough, according to Malhotra. 'Law will take its course on IndusInd fraud. RBI will not be failing in its duty if any step has to be taken,' added Malhotra. RBI Deputy Governor J Swaminathan assured that there seems to be no systemic impact arising from the IndusInd Bank issue, while the central bank will keep monitoring the banking system.
